Sanofi: Colorectal Neoplasms trials
The registry lists 24 Colorectal Neoplasms studies with Sanofi as lead sponsor. 1 are open to participants now and 9 have results posted.
Phase 1 5Phase 2 9Phase 3 10Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)CompletedNCT05104567Phase 2Results posted
- Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer PatientTerminatedNCT01955629Phase 1/2Results posted
- A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in JapanCompletedNCT01882868Phase 2Results posted
- Colorectal Cancer MetastaticCompletedNCT01670721Phase 3Results posted
- A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin ChemotherapyCompletedNCT01661270Phase 3Results posted
- Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based RegimenCompletedNCT01571284Phase 3Results posted
- Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal CancerCompletedNCT00851084Phase 2Results posted
- Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based RegimenCompletedNCT00561470Phase 3Results posted
- A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in PatientsCompletedNCT00454116Phase 2Results posted
- Resection ObservatoryCompletedNCT05178745
- Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal CancerWithdrawnNCT02085005Phase 2
- Oral Glutamine in the Prevention of Oxaliplatin-induced NeurotoxicityCompletedNCT01087658Phase 3
- Colorectal Cancer RECHALLENGEWithdrawnNCT00988897Phase 2
- Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal CancerCompletedNCT00921661Phase 1
- Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based RegimensTerminatedNCT00603577Phase 3
- Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal CancerCompletedNCT00496509Phase 1
- A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal CancerTerminatedNCT00403052Phase 1
- TREE-2: Three Regimens of Eloxatin in Advanced Colorectal CancerCompletedNCT00399750Phase 2
- Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.CompletedNCT00305188Phase 3
- XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV ChemotherapyCompletedNCT00272051Phase 3
- CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal CancerTerminatedNCT00129870Phase 4
- Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal CancerCompletedNCT00012389Phase 3
- Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal CancerStatus unknownNCT00008281Phase 3